HK1215671A1 - 利用阿普斯特來治療銀屑病關節炎的方法 - Google Patents

利用阿普斯特來治療銀屑病關節炎的方法

Info

Publication number
HK1215671A1
HK1215671A1 HK16103616.0A HK16103616A HK1215671A1 HK 1215671 A1 HK1215671 A1 HK 1215671A1 HK 16103616 A HK16103616 A HK 16103616A HK 1215671 A1 HK1215671 A1 HK 1215671A1
Authority
HK
Hong Kong
Prior art keywords
apremilast
treatment
psoriatic arthritis
psoriatic
arthritis
Prior art date
Application number
HK16103616.0A
Other languages
English (en)
Inventor
羅伯特．達
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1215671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of HK1215671A1 publication Critical patent/HK1215671A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
HK16103616.0A 2013-03-14 2016-03-30 利用阿普斯特來治療銀屑病關節炎的方法 HK1215671A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782880P 2013-03-14 2013-03-14
PCT/US2014/025171 WO2014151180A1 (en) 2013-03-14 2014-03-13 Treatment of psoriatic arthritis using apremilast

Publications (1)

Publication Number Publication Date
HK1215671A1 true HK1215671A1 (zh) 2016-09-09

Family

ID=50549444

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103616.0A HK1215671A1 (zh) 2013-03-14 2016-03-30 利用阿普斯特來治療銀屑病關節炎的方法

Country Status (10)

Country Link
US (1) US9872854B2 (zh)
KR (1) KR20150126618A (zh)
CN (1) CN105050624A (zh)
AU (1) AU2014235273A1 (zh)
BR (1) BR112015020584A2 (zh)
HK (1) HK1215671A1 (zh)
IL (1) IL239499A0 (zh)
MX (1) MX2015008685A (zh)
NZ (1) NZ628320A (zh)
WO (1) WO2014151180A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2420497T3 (en) 2006-09-26 2016-03-07 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
RS58523B1 (sr) 2010-02-11 2019-04-30 Celgene Corp Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
TWI601722B (zh) 2011-03-11 2017-10-11 西建公司 ３-（５-胺基-２-甲基-４-氧基-４ｈ-喹唑啉-３-基）-六氫吡啶-２，６-二酮之固體型式及其醫藥組合物及用途
ES2814952T3 (es) 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
CN105588886B (zh) * 2014-11-18 2020-01-31 重庆医药工业研究院有限责任公司 一种采用液相色谱法测定阿普斯特及其制剂中杂质的方法
CN104458961A (zh) * 2014-12-11 2015-03-25 南京艾德凯腾生物医药有限责任公司 阿普斯特有关物质检测方法
WO2016146990A1 (en) * 2015-03-19 2016-09-22 Cipla Limited Improved process for the preparation of apremilast
CN106727344A (zh) * 2015-11-19 2017-05-31 常州爱诺新睿医药技术有限公司 一种无定型阿普斯特的固体分散体及其制备方法
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105935350B (zh) * 2015-12-18 2018-11-16 重庆两江药物研发中心有限公司 一种阿普斯特缓释植入剂及其制备方法
EP3395334A4 (en) * 2015-12-24 2019-07-31 Jiangsu Hengrui Medicine Co. Ltd. PREPARATION FOR EXTENDED RELEASE OF APREMILAST
CN108181401B (zh) * 2018-01-26 2020-07-31 华侨大学 一种阿普斯特片有效成分的含量测定方法
CN109568302B (zh) * 2018-11-01 2021-07-16 郑州大学第一附属医院 一种治疗晚期肝癌的药物复合物及其应用
JP2022537877A (ja) * 2019-04-30 2022-08-31 セルジーン コーポレイション アプレミラストおよびｔｙｋ２阻害剤を含む併用療法
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
EP4132570A1 (en) * 2020-04-08 2023-02-15 Nostrum Pharmaceuticals, LLC Compositions and methods using interferon for treating viral respiratory infections
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2023121670A1 (en) * 2021-12-23 2023-06-29 Amgen Inc. Oral suspension of apremilast
CN116019762B (zh) * 2022-09-19 2024-06-07 厦门大学 一种用于治疗银屑病的药物组合物、制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CA2590903A1 (en) 2004-12-13 2006-06-22 Celgene Corporation Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
ES2442717T3 (es) * 2008-01-18 2014-02-13 Atopix Therapeutics Limited Compuestos que tienen actividad antagonista de CRTH2
WO2009120296A1 (en) 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
PT2334639E (pt) 2008-09-10 2013-04-26 Celgene Corp Processos para a preparação de compostos de aminossulfona
MX2012004741A (es) * 2009-11-19 2012-05-22 Celgene Corp Apremilast para el tratamiento de sarcoidosis.

Also Published As

Publication number Publication date
MX2015008685A (es) 2015-10-05
CN105050624A (zh) 2015-11-11
IL239499A0 (en) 2015-08-31
BR112015020584A2 (pt) 2017-07-18
KR20150126618A (ko) 2015-11-12
AU2014235273A1 (en) 2015-07-09
AU2014235273A2 (en) 2015-07-23
US20140301980A1 (en) 2014-10-09
US20150174100A2 (en) 2015-06-25
NZ628320A (en) 2017-04-28
US9872854B2 (en) 2018-01-23
WO2014151180A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
HK1215671A1 (zh) 利用阿普斯特來治療銀屑病關節炎的方法
HK1219236A1 (zh) 猝倒的治療
GB2518853B (en) Voltage source converter
PL3071230T3 (pl) Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania
EP2968273A4 (en) METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
GB2519793B (en) Voltage source converter
HK1221164A1 (zh) 噬菌體療法
HK1224324A1 (zh) 煤處理
IL248627A0 (en) Amorphous form of apramilst
GB201304872D0 (en) Treatment
GB201610529D0 (en) Waste treatment process
HK1208396A1 (zh) 電位治療儀
HK1195202A2 (zh) 穴位尋找關節炎治療儀
GB201420194D0 (en) Apparatus for the provision of power
IL239812A0 (en) Method and composition for the treatment of arthritis and osteoarthritis
GB201307310D0 (en) Treatment
HK1225635A1 (zh) 用於類風濕性關節炎治療的組合物及使用該組合物的方法
ZA201601626B (en) Treatment of gases
HK1208395A1 (zh) 電位治療儀
GB201408752D0 (en) Arthritis treatment
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
HRP20190035T1 (hr) Obrada krutina s visokim sadržajem sumpora
GB201321099D0 (en) Waste treatment process
GB201320130D0 (en) Apparatus for the provision of power
GB201320126D0 (en) Apparatus for the provision of power